Actuate Therapeutics (NASDAQ:ACTU) on Saturday announced encouraging results from a Phase 2 clinical trial testing its experimental cancer drug, elraglusib, in combination with standard chemotherapy in patients with advanced pancreatic cancer.
The findings, shared Saturday at the 2025 American Society of